Administration of TLR3 agonists is extraordinarily effective in inducing maturation of type one conventional DCs (cDC1s) [17, 18], which are necessary for inducing cellular immunity and are linked to increased survival in patients with certain cancer types due to their efficient processing and cross-presentation of exogenous antigens on MHC class I molecules to activate CD8 + T cells and prime TH1 cell responses [19–22]. The gene discussed is CD8A; the disease is cancer.